615. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster I
0 activities
A Comprehensive Analysis of FLT3 Mutation Profiles and Clinical Outcomes in Adult Patients with Acute Myeloid Leukemia: A Single Institution Experience
1 activities
A Comprehensive Analysis of FLT3 Mutation Profiles and Clinical Outcomes in Adult Patients with Acute Myeloid Leukemia: A Single Institution Experience
Allogeneic Hematopoietic Cell Transplantation in Adult Acute Myeloid Leukemia with t(16;21)(p11;q22)
1 activities
Allogeneic Hematopoietic Cell Transplantation in Adult Acute Myeloid Leukemia with t(16;21)(p11;q22)
Association between Body Mass Index and Outcomes in Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax
1 activities
Association between Body Mass Index and Outcomes in Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax
Clinical Features and Prognostic Nomogram for Therapy-Related Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation
1 activities
Clinical Features and Prognostic Nomogram for Therapy-Related Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation
Day 30 Mortality in Patients with AML: A Single Center Analysis Based on 1036 Patients
1 activities
Day 30 Mortality in Patients with AML: A Single Center Analysis Based on 1036 Patients
Deep Learning Models for Predicting Overall Survival of Acute Myeloid Leukemia Using Short-Term Longitudinal Blood Measurements and the Omop Common Data Model
1 activities
Deep Learning Models for Predicting Overall Survival of Acute Myeloid Leukemia Using Short-Term Longitudinal Blood Measurements and the Omop Common Data Model
Epidemiological Trends in Incidence, Death and Associated Risk Factors of Leukemia 1990-2021 and Projection to 2040
1 activities
Epidemiological Trends in Incidence, Death and Associated Risk Factors of Leukemia 1990-2021 and Projection to 2040
IDH Mutated AML Is Associated with Increased Risk of Pulmonary Morbidity and Mortality during Induction Chemotherapy
1 activities
IDH Mutated AML Is Associated with Increased Risk of Pulmonary Morbidity and Mortality during Induction Chemotherapy
Impact of Co-Mutations, Monocytic Differentiation, and Choice of Hypomethylating Agent Combined with Venetoclax on the Predictive Value of Molecular Prognostic Risk Signature in Newly Diagnosed AML Patients
1 activities
Impact of Co-Mutations, Monocytic Differentiation, and Choice of Hypomethylating Agent Combined with Venetoclax on the Predictive Value of Molecular Prognostic Risk Signature in Newly Diagnosed AML Patients
Intensive Chemotherapy Vs. Azacitidine + Venetoclax for AML with Secondary Mutations
1 activities
Intensive Chemotherapy Vs. Azacitidine + Venetoclax for AML with Secondary Mutations
Less May be More: The Impact of Post-Remission Intensive (IC) Consolidation Cycles on Outcomes in Newly Diagnosed Acute Myeloid Leukemia Receiving IC + Venetoclax
1 activities
Less May be More: The Impact of Post-Remission Intensive (IC) Consolidation Cycles on Outcomes in Newly Diagnosed Acute Myeloid Leukemia Receiving IC + Venetoclax
Leukemia Physician’s Perspective on Transplant in Patients with TP53 Mutated Acute Myeloid Leukemia
1 activities
Leukemia Physician’s Perspective on Transplant in Patients with TP53 Mutated Acute Myeloid Leukemia
Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients between 65-75 Years and Treated with Intensive Induction Chemotherapy Versus Hypomethylating Agents and Venetoclax: A Propensity Score Adjusted Cohort Study
1 activities
Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients between 65-75 Years and Treated with Intensive Induction Chemotherapy Versus Hypomethylating Agents and Venetoclax: A Propensity Score Adjusted Cohort Study
Toxicity and Efficacy of Isavuconazole Vs Voriconazole As Anti-Fungal Prophylaxis for Patients with Acute Myeloid Leukemia
1 activities
Toxicity and Efficacy of Isavuconazole Vs Voriconazole As Anti-Fungal Prophylaxis for Patients with Acute Myeloid Leukemia
Treatment Outcomes in Acute Promyelocytic Leukemia Patients Using a Uniform ATRA + ATO Consolidation Therapy Regimen across All Risk Groups: A Single Centre Study from India
1 activities
Treatment Outcomes in Acute Promyelocytic Leukemia Patients Using a Uniform ATRA + ATO Consolidation Therapy Regimen across All Risk Groups: A Single Centre Study from India
Venetoclax Combined with Intensive Chemotherapy As an Induction Chemotherapy in Newly Diagnosed FLT3-ITD Positive AML
1 activities
Venetoclax Combined with Intensive Chemotherapy As an Induction Chemotherapy in Newly Diagnosed FLT3-ITD Positive AML
Venetoclax with Hypomethylating Agents Compared with Priming Regimens for Newly Diagnosed Patients with Acute Myeloid Leukemia with Myelodysplasia Related Changes: A Single Center Retrospective Study
1 activities
Venetoclax with Hypomethylating Agents Compared with Priming Regimens for Newly Diagnosed Patients with Acute Myeloid Leukemia with Myelodysplasia Related Changes: A Single Center Retrospective Study